AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration.

ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company’s commitment to addressing difficult-to-treat tumors.

Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)’s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV’s robust long-term performance and future revenue potential as its innovative pipeline matures.

While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.